Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thank you Leaf1 and Matterhorn. It is always good to reinforce existing knowledge with additional relevant information. Regards.
Leaf1 - that note from Numis is correct re standalone. The company signed up distribution and production partners to ensure they can provide the product to the market in case there’s no partner at that stage. It’s part of the de-risking strategy and increases shareholder value.
This is from a Jan 2021 interview with Richard re production.
‘ Synairgen has a partnership with a company in Germany and a second manufacturing source in the US “just to cope with the potential demand”.
The group is also working with two companies for fill-finish activities: Catalent Biologics (US:CTLT) and Thermo Fisher (US:TMO). “It’s all about contingency”, Mr Marsden said, noting the group also has two partnerships for aerosol delivery systems.’
https://www.investorschronicle.co.uk/news/2021/01/14/with-vaccine-roll-outs-underway-what-does-the-future-hold-for-covid-19-treatment/
Kevin
1. I am looking at the weekly chart to see if the support line holds.
2. As a result of some profits elsewhere from a top slice, I have ensured that my cash at hand is equal or better to the Synairgen investment.
3. Whatever its says in the 2020 report, alongside keep up to date on competition and keep an eye for new Government iniatives to help the NHS.
The last thing the NHS needs is another winter back log. The NHS needs help to improve how they deliver the service and how industry can help them in that regard. This may give Synairgen a really important way into the NHS for COPD, Covid-19 (in Part where it has relevance and influenza) where patients arrive with acute exacerbations. When all these are tackled together the price of treatment can go down as they may all coincide with the same early intervention protocol.
All the best
Tony
TLW - the below was more in context of takeover rather than production or a JV, but you may find it interesting:
Synairgen has a stated strategy for a standalone future and will continue to pursue that in order to create shareholder value.
That is a snippet of corres I had with Numis.
RM’s comments have been so vague that they can be read any which way, in my humble opinion.
This board varies between ‘don’t sell out too cheap’ to ‘we’ve always known we need a big pharmaceutical to get this out there’ depending on where the SP is on any given day.
Leaf
TLW - Ritch raised ~£50m to ramp up production months before any whiff of Activ 2 and talked about 100s thousands treatments per month.
https://www.lse.co.uk/rns/SNG/placing-and-open-offer-hwyvj20u13tq1ig.html
That was from RNS though, so I'm not sure if we can trust it - could just be fake news. The Cult's Great Book of Synairgen has got to have the real truths in it, but I never got sent a copy because I refused to sacrifice a baby as part of the cult initiation ritual.
_Mr_Big.
I agree with your comment, although I believe (from my interpretation of previous comments from Richard Marsden) that the company is primed to bring in external partners to considerably increase production levels (of SNG001) in the event of a positive outcome from the ACTIV-2 trials, accompanied by regulatory authorisation for its emergency use. I am prepared to accept a reprimand from anyone who has evidence to contradict my assertion.
Regards.
My correspondence was all about P3 recruitment sites.
Tony
Dear Anthony
Thank you for your interest and support of Synairgen. The Company is heading towards announcing its Full Year Results 2020 in May and aims to provide a suitable update at that point.
Thank you again for your continued support.
Kind regards,
Kris
Kevin - do you expect to see anything in the results that can improve the SP? What revenue figures do you expect to see? Maybe a profit for the year and a promise of dividends?
The only good thing that can possibly come out of it would be a huge figure in SNG stock ready to be sold as soon as an authorisation is granted. But if that's really the case, then why delay the promised manufacturing update by 4 months?
@Kevin
It will affect the SP in one of three ways
1. Nothing will happen, price stays the same.
2. it will go up
3. it will go down.
Your guess is as good as anyone else.....
SYN past performance would most likely deter most investors, we need to take a position based on the P2 and P3 data?
P2 data reflects the position of SNG potentially having a therapeutic that gives a positive effect in breathless patients hospital bound. Expecting P3 to back this up, this being the case SNG should have a therapeutic that can be deployed in hospital bound cases.
This all tends to tie up with RM body language in his presentations over the last 12 months which indicate SNG clearly know where their drug adds valve. SNG are taking full advantage of external funding to get through the data gathering phases.
I know you didn't ask me, nor will it stop people speculating, but do you really think anyone might know the answer to that one?
Tony
How do you think that is likely to affect the SP?
Thanks Tony
The company are in the process of producing their report for 2020 and we should receive updates. Hopefully it will be just after the next bank holiday and not before it. (Message from Kris).